FSD Pharma Inc, (CSE:HUGE) is pleased to announce the launch of a comprehensive sponsored research program in Tel Aviv University together with its strategic R&D partner, SciCann Therapeutics Inc. (“SciCann”), focused on the cardiovascular disease field.
FSD Pharma Inc, (CSE:HUGE) is pleased to announce the launch of a comprehensive sponsored research program in Tel Aviv University together with its strategic R&D partner, SciCann Therapeutics Inc. (“SciCann”), focused on the cardiovascular disease field. The new research program is aimed at the development of novel and proprietary cannabinoid-based treatments for the prevention and treatment of atherosclerosis, the underlying factor for most cases of stroke and cardiac stenosis events in the western world.
Dr. Zohar Koren, Co-founder and CEO of SciCann stated, “The prevalence of Coronary Artery Disease (CAD) among adults in North America is estimated at 8% of the population and considered to be the number one killer disease in the western world. There is a high unmet need for novel, safe and natural therapies that will ameliorate the damage caused by atherosclerotic plaques to the arteries and cardiovascular system and we believe that smart and targeted modulation of the endocannabinoid system may offer a new approach to treat this devastating progressive disease. We are highly excited to launch this new research program in Tel Aviv University and use the sophisticated and advanced labs that it offers for the execution of this program.”
Thomas Fairfull, President and CEO of FSD Pharma stated, “With the global Coronary Artery Disease therapeutics market projected to surpass $15 billion in 20181 and the potential to tap this huge market with safe and effective cannabinoid-based therapies, we are highly encouraged to launch this new research program in the heart of the thriving cannabis science and R&D ecosystem of Israel. This program marks another very important milestone for FSD on its way to becoming a leading supplier of superior and differentiated medical cannabis therapies for patients throughout Canada and the world. Together with our Scientific R&D partner, SciCann Therapeutics, we are now putting a strong emphasis on the development of novel and disruptive cannabinoid-based therapies for the world’s most debilitating and lethal diseases, and Coronary Artery Disease is definitely a prime target to focus on in our endeavors.”
About FSD Pharma (CSE:HUGE) (OTCQB: FSDDF) (FRA: 0K9)
FSD Pharma through its wholly-owned subsidiary FV Pharma, is a licensed producer of marijuana under the Access to Cannabis for Medical Purposes Regulations (ACMPR) having received its cultivation license on October 13, 2017. Headquartered at the former Kraft plant in Cobourg, Ontario, approximately an hour’s drive from Toronto, FV Pharma management’s mission is to transform the facility into the largest hydroponic indoor cannabis facility in the world. FV Pharma intends to target all legal aspects of the cannabis industry, including cultivation, processing, manufacturing, extracts and research and development.
About SciCann Therapeutics
SciCann Therapeutics is a Canadian-Israeli specialty pharmaceutical company, dedicated to the development and commercialization of novel and disruptive pharmaceutical products that target and modulate the endocannabinoid system. SciCann Therapeutics is active in the fields of oncology, pain management, neurodegenerative diseases and inflammatory disorders, and develops a line of proprietary products for the treatment of chosen life- threatening conditions that present a high level of unmet need.
SciCann has created a network of collaborations with leading academic centers and medical institutions in Israel in order to engage in cutting edge science and rigorous clinical studies to develop its products, while using the permissive regulatory climate in Israel for performing its R&D programs quickly and efficiently.
Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Corporation’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the development of the Corporation’s indoor cannabis facility and its business goals and objectives. The forward-looking information contained in this press release is made as of the date hereof, and the Corporation is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward looking-information. The foregoing statements expressly qualify any forward-looking information contained herein.
Neither the Canadian Securities Exchange nor its regulation services provider accept responsibility for the adequacy or accuracy of this release.
For further information: ON BEHALF OF FSD PHARMA: Thomas Fairfull, President and Chief Executive Officer, Email: email@example.com, Telephone: (905) 686-7079; ON BEHALF OF SCICANN:Dr. Zohar Koren, Chief Executive Officer, Email: firstname.lastname@example.org, Cell: +972-52-733-1424